Inactive Instrument

Press Releases Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Real-time Estimate Cboe Europe Other stock markets 07:45:48 2024-04-29 am EDT			5-day change	1st Jan Change
27.9 ^SEK	-82.91%		-5.78%	-38.73%

Apr. 18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18	Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma Q1 - Improved European launch support	Apr. 19	AQ
Hansa Biopharma interim report January-March 2024	Apr. 18	AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	Apr. 11	AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	Apr. 02	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	Mar. 21	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	Feb. 22	AQ
Hansa Biopharma - Improved sales prospects	Feb. 05	AQ
Hansa Biopharma Year-end report January-December 2023	Feb. 02	AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	Jan. 06	AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	Dec. 15	AQ
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	Dec. 14	AQ
Hansa Biopharma Nomination Committee formed	Dec. 13	AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	Dec. 08	AQ
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)	Dec. 07	AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	Dec. 05	AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	Nov. 27	AQ
Hansa Biopharma Q3 update - Slow progress ahead of 2024	23-10-27	AQ
Hansa Biopharma Interim Report January-September 2023	23-10-26	AQ
Hansa Biopharma - Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	23-10-18	AQ
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study	23-10-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Press Releases

Filters